Showing 1111-1120 of 1572 results for "".
- New Trial of 'Pill-on-a-Thread' Brings Screening for Oesophageal Cancer Closerhttps://reachmd.com/news/new-trial-of-pill-on-a-thread-brings-screening-for-oesophageal-cancer-closer/2456802/The capsule sponge, known as the pill-on-a-thread, is a quick and simple test for Barrett’s oesophagus, a condition that can be a precursor to cancer. Heartburn is a common symptom of Barrett’s oesophagus, a changing of cells in the food pipe. The BEST4 trial launched at Adden
- Community Cancer Care Linked with Poorer Outcomes for Patients with a Common Head and Neck Cancerhttps://reachmd.com/news/community-cancer-care-linked-with-poorer-outcomes-for-patients-with-a-common-head-and-neck-cancer/2456734/FOR IMMEDIATE RELEASENewswise — Care for patients with human papillomavirus (HPV)-related squamous cell cancers of the oropharynx (an area in back of the throat) is shifting toward community cancer centers, but patients treated in this setting may be less likely to surviv
- New Series Spotlights Real Stories of MCC Patientshttps://reachmd.com/news/new-series-spotlights-real-stories-of-mcc-patients/2484808/The Skin Cancer Champions Community announced that it will launch its Living With: Merkel Cell Carcinoma (MCC) web series on Wednesday, January 14, 2026, from 12:00 to 1:00pm EST via Zoom. According to a release from the group, the premiere episode,
- Innovative Nanoparticle Strategies in Targeting MSS Colorectal Cancer: pH-Responsive Systems and Their Translational Potentialhttps://reachmd.com/news/innovative-nanoparticle-strategies-in-targeting-mss-colorectal-cancer-ph-responsive-systems-and-their-translational-potential/2484550/pH‑responsive solid lipid nanoparticles enable tumor‑selective delivery and immune reprogramming in microsatellite‑stable (MSS) colorectal cancer, converting immune‑excluded tumors into T cell–permissive microenvironments. In preclinical models these nanoparticles showed tumor‑prefe
- Interim Phase 2 Data Reveal Efficacy and Strategic Potential of KYV-101 in Generalized Myasthenia Gravishttps://reachmd.com/news/interim-phase-2-data-reveal-efficacy-and-strategic-potential-of-kyv-101-in-generalized-myasthenia-gravis/2484058/Interim Phase 2 data from Kyverna Therapeutics’ KYSA‑6 study indicate KYV‑101 produced early efficacy signals and an acceptable safety profile in generalized myasthenia gravis (gMG). KYV‑101 is a fully human, autologous CD19 CAR T‑cell therapy intended to induce deep
- Unraveling the Role of DIORA1 in Autoimmune Rheumatic Diseaseshttps://reachmd.com/news/unraveling-the-role-of-diora1-in-autoimmune-rheumatic-diseases/2483575/Early laboratory findings suggest DIORA1 may influence cell motility relevant to inflammatory processes, but any relevance to rheumatoid arthritis or lupus remains hypothetical and requires validation in peer‑reviewed studies, suggesting potential avenues for therapeutic exploration
- Lung Cancer Treatment: Evaluating Surgery, Radiation, and Novel Therapieshttps://reachmd.com/news/lung-cancer-treatment-evaluating-surgery-radiation-and-novel-therapies/2483578/As lung cancer persists as a formidable adversary in oncology, the clinical landscape for Non-Small Cell Lung Cancer (NSCLC) treatment is rapidly evolving. With the rising prominence of stereotactic body radiation therapy (SBRT) for medically inoperable early-stage disease—as endors
- Phase I Clinical Insights on Obrixtamig: Targeting DLL3-Positive Cancershttps://reachmd.com/news/phase-i-clinical-insights-on-obrixtamig-targeting-dll3-positive-cancers/2483521/In the relentless pursuit to conquer aggressive forms of cancer, obrixtamig represents a beacon of hope for those battling DLL3-positive carcinomas. Small cell lung cancer (SCLC) presents unique challenges in oncologic care, with exploration extending to other DLL3‑positive neuroendocrine t
- NSCLC in Focus at WCLC: 3 Pivotal Trials Shaping the Next Wave of Treatmenthttps://reachmd.com/news/nsclc-in-focus-at-wclc-3-pivotal-trials-shaping-the-next-wave-of-treatment/2483234/As clinicians and researchers convene in Barcelona for the IASLC 2025 World Conference on Lung Cancer (WCLC), the stakes are high for new data poised to shift the therapeutic landscape for non-small cell lung cancer (NSCLC). Despite steady progress in immunotherapie
- Immune Checkpoint Inhibitors and the Future of Cancer Treatmenthttps://reachmd.com/news/immune-checkpoint-inhibitors-and-the-future-of-cancer-treatment/2483019/Immune checkpoint inhibitors have revolutionized cancer treatment by re‑engaging the body's immune response, offering new hope in challenging cases such as small cell lung cancer (SCLC). For extensive‑stage SCLC, adding atezolizumab or durvalumab to platinum–etoposide is now a first‑line st